# EDGAR Filing Document

**Accession Number:** 0001110803
**File Stem:** 0001110803-26-000006
**Filing Date:** 2026-1
**Character Count:** 10600
**Document Hash:** e78cb64d0fc147c83c8bbbc62b9e0329
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001110803-26-000006.hdr.sgml**: 20260108

**ACCESSION NUMBER**: 0001110803-26-000006

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20260108

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260108

**DATE AS OF CHANGE**: 20260108

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ILLUMINA, INC.
- **CENTRAL INDEX KEY:** 0001110803
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 330804655
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1228

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35406
- **FILM NUMBER:** 26520122

**BUSINESS ADDRESS:**
- **STREET 1:** 5200 ILLUMINA WAY
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122
- **BUSINESS PHONE:** 8582024500

**MAIL ADDRESS:**
- **STREET 1:** 5200 ILLUMINA WAY
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ILLUMINA INC
- **DATE OF NAME CHANGE:** 20000331

?xml version='1.0' encoding='ASCII'? ilmn-20260108

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 4, 2026**![ilmnlogoa19.jpg](ilmn-20260108_g1.jpg)

**Illumina, Inc.**

(Exact name of registrant as specified in its charter)

**001-35406**

(Commission File Number)

---

| | |
|:---|:---|
| **Delaware** | **33-0804655** |
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) |

---

**5200 Illumina Way, San Diego, CA 92122**

(Address of principal executive offices) (Zip code)

**(858) 202-4500**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.01 par value | ILMN | The NASDAQ Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐&nbsp;&nbsp;&nbsp;&nbsp;

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. □&nbsp;&nbsp;&nbsp;&nbsp;

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 4, 2026, Everett Cunningham, Chief Commercial Officer, notified Illumina, Inc. that he will be resigning effective as of January 16, 2026.

------

**Item 7.01 Regulation FD Disclosure.**

On January 8, 2026, the Company issued a press release to announce certain changes in the Company's management, including the resignation of Everett Cunningham, Chief Commercial Officer, as of January 16, 2026. Such press release is attached hereto as <u>[Exhibit 99.1](ex991pressrelease1826.htm)</u> and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including <u>[Exhibit 99.1](ex991pressrelease1826.htm)</u>, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

------

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<u>[99.1](ex991pressrelease1826.htm)</u>&nbsp;&nbsp;&nbsp;&nbsp;Illumina, Inc. Press Release, dated January 8, 2026

104&nbsp;&nbsp;&nbsp;&nbsp;Cover Page Interactive Data File (embedded within the Inline XBRL document)&nbsp;&nbsp;&nbsp;&nbsp;

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | **ILLUMINA, INC.** | **ILLUMINA, INC.** |
| Date: | January 8, 2026 | By: | /s/ SCOTT DAVIES |
|  |  | Name: | Scott Davies |
|  |  | Title: | Chief Legal Officer |

---

------

**Exhibit Index**

---

| | |
|:---|:---|
| Exhibit Number | Description |
| <u>[99.1](ex991pressrelease1826.htm)</u> | Illumina, Inc. Press Release, dated January 8, 2026 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

## Exhibit 99.1

---

| |
|:---|
| ![image1.jpg](image1.jpg) |
| ![image1.jpg](image1.jpg) |
| ![image1.jpg](image1.jpg) |
| ![image1.jpg](image1.jpg) |

---

&nbsp;&nbsp;&nbsp;&nbsp;

Illumina Appoints Dr. Eric Green as Chief Medical Officer

*Veteran genomics leader joins Illumina to advance global medical strategy*

*Illumina chief commercial officer to depart for role as a life science tools company CEO*

SAN DIEGO, Jan. 8, 2026 /PRNewswire/ — Today, Illumina, Inc. (NASDAQ: ILMN) announced the appointment of Eric D. Green, M.D., Ph.D., as Chief Medical Officer (CMO), effective February 2. In this role reporting to the CEO, Dr. Green will accelerate the company's mission to drive a revolution in medicine by unlocking the power of the genome. Dr. Green will serve as a key scientific and medical leader representing Illumina, helping advance the clinical use of genomics, expand access to precision medicine solutions, and increase the diversity of genomics data.

Dr. Green's unique expertise, knowledge, and influence with partners, KOLs, and medical professionals will serve as a critical component in Illumina's strategic efforts to improve human health through genomics on a global level. As CMO, Dr. Green will be part of Illumina's Executive Leadership Team and will be a champion for the company's mission, technology roadmap, and growing clinical impact.

"Eric is a once-in-a-generation leader in genomics whose career has closely tracked the evolution of the field itself," said Jacob Thaysen, chief executive officer of Illumina. "He has spent decades championing the role of genomics in medicine and building trust across the scientific, clinical, and public health communities. Eric's counsel will be invaluable in helping Illumina extend and deepen the medical impact of its innovations for people worldwide."

Dr. Green is widely regarded as one of the most influential leaders in genomics since the field's inception. He joins Illumina after more than three decades at the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health. As the NHGRI Director from 2009 to 2025, he helped guide the transformation of genomics from a primarily research-driven field into a foundational element of modern medicine and public health.

"Illumina has been instrumental to the growth and evolution of genomics, and I am excited to join the company at a time when genomic information is becoming increasingly important in clinical care," said Dr. Green. "Illumina sits at the center of the growing omics ecosystem, and the company is uniquely positioned to help shape the next phase of genomic medicine."

Dr. Green trained as a physician scientist, earning an M.D. and Ph.D. from Washington University School of Medicine. During his residency training in clinical pathology (laboratory medicine), he launched his career in genomics. Several years later, he became a beginning-to-end participant in the Human Genome Project and emerged as an international genomics leader.

------

**Illumina congratulates Everett Cunningham on appointment**

Illumina also announced the departure of chief commercial officer Everett Cunningham, who has been appointed as CEO of a life science tools company.

"We are thankful for Everett's leadership during a crucial time of transition for Illumina. For our path forward, we have strong leadership in place, continue to make excellent progress towards our long-term goals, and are confident in our progress," said Jacob Thaysen, chief executive officer at Illumina. Thaysen will act as interim chief commercial officer until a permanent successor to Cunningham is named.

Illumina will participate in next week's J.P. Morgan Healthcare Conference, where Jacob Thaysen, CEO, will speak on Tuesday, January 13, at 7:30 AM Pacific Time.

------

**About Illumina**

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

**Contacts**

**Investors:**

Illumina Investor Relations

858.291.6421 IR@illumina.com

**Media:**

Christine Douglass

PR@illumina.com

<br>